Probability of HBsAg Loss After Nucleo(s)tide Analogue Withdrawal Depends on HBV Genotype and Viral Antigen Levels

This study was a pooled analysis of previously published cohorts 2 prospective multi centre studies (N = 1216). Data collected from done in patients centres at Europe and Asia (CREATE group)1 were with data cohort Taiwanese patients.2 All treated only nucleos(t)ide analogues (NUCs) had undetectable Hepatitis B virus (HBV) DNA envelope Antigen (HbeAg) negative status the time treatment cessation. Of all patients, 23.9% where HBeAg positive pre-treatment, 91% Asians 71.2% infected either Genotype or C.